A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer (Q73923794)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

phase I clinical trial

1 reference

inferred from title

metastatic colon cancer

1 reference

1 reference

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

C Garufi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

F Lévi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

A M Aschelter

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

R Pace

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

S Giunta

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

C Nisticò

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

D A Gallà

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

F Franchi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

C Narduzzi

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

E Terzoli

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 September 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

1566-1571

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Effect of biological time on the determination of the LD50 of 5-fluorouracil in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Diurnal variation in labelling index in human buccal epithelium.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Circadian rhythm of cellular proliferation in the human rectal mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Chronotherapy with 5-fluorouracil and folinic acid in advanced colorectal carcinoma. Results of a chronopharmacologic phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the Germa

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900133-0

7 January 2021

10.1016/S0959-8049(97)00133-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9389916%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference